These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33776997)

  • 21. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons.
    Melo JB; Sousa C; Garção P; Oliveira CR; Agostinho P
    Eur J Neurosci; 2009 Feb; 29(3):455-64. PubMed ID: 19222556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on Alzheimer drugs (galantamine).
    Raskind MA
    Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of α7nAChR in controlling the anti-inflammatory/anti-arthritic action of galantamine.
    Gowayed MA; Rothe K; Rossol M; Attia AS; Wagner U; Baerwald C; El-Abhar HS; Refaat R
    Biochem Pharmacol; 2019 Dec; 170():113665. PubMed ID: 31606410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of increasing body mass index on cardio-metabolic risk and biomarkers of oxidative stress and inflammation in nascent metabolic syndrome.
    Pahwa R; Adams-Huet B; Jialal I
    J Diabetes Complications; 2017 May; 31(5):810-813. PubMed ID: 28285929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
    Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
    J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Galantamine for Alzheimer's disease.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2004 Oct; (4):CD001747. PubMed ID: 15495017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent alteration in inflammatory biomarker gene expression and oxidative stress: how aerobic training and vitamin D improve T2DM.
    Hoseini R; Rahim HA; Ahmed JK
    BMC Complement Med Ther; 2022 Jun; 22(1):165. PubMed ID: 35733163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome.
    Raygan F; Rezavandi Z; Dadkhah Tehrani S; Farrokhian A; Asemi Z
    Eur J Nutr; 2016 Dec; 55(8):2357-2364. PubMed ID: 26385228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Galantamine in Alzheimer's disease.
    Razay G; Wilcock GK
    Expert Rev Neurother; 2008 Jan; 8(1):9-17. PubMed ID: 18088197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fumaric acid esters can block pro-inflammatory actions of human CRP and ameliorate metabolic disturbances in transgenic spontaneously hypertensive rats.
    Šilhavý J; Zídek V; Mlejnek P; Landa V; Šimáková M; Strnad H; Oliyarnyk O; Škop V; Kazdová L; Kurtz T; Pravenec M
    PLoS One; 2014; 9(7):e101906. PubMed ID: 25010431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular protective effect of pioglitazone on oxidative stress in rats with metabolic syndrome.
    Bilginoglu A
    J Chin Med Assoc; 2019 Jun; 82(6):452-456. PubMed ID: 30932940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors.
    Klugman A; Naughton DP; Isaac M; Shah I; Petroczi A; Tabet N
    J Alzheimers Dis; 2012; 30(3):467-74. PubMed ID: 22451323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis.
    Panahi Y; Hosseini MS; Khalili N; Naimi E; Majeed M; Sahebkar A
    Clin Nutr; 2015 Dec; 34(6):1101-8. PubMed ID: 25618800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic syndrome-associated cognitive decline in mice: Role of minocycline.
    Mukherjee A; Mehta BK; Sen KK; Banerjee S
    Indian J Pharmacol; 2018; 50(2):61-68. PubMed ID: 30100653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An update on the pharmacology of galantamine.
    Villarroya M; García AG; Marco-Contelles J; López MG
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway.
    Pavlov VA; Parrish WR; Rosas-Ballina M; Ochani M; Puerta M; Ochani K; Chavan S; Al-Abed Y; Tracey KJ
    Brain Behav Immun; 2009 Jan; 23(1):41-5. PubMed ID: 18639629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status and new developments with galantamine in the treatment of Alzheimer's disease.
    Tariot P
    Expert Opin Pharmacother; 2001 Dec; 2(12):2027-49. PubMed ID: 11825333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of sumac supplementation on insulin resistance, inflammation, oxidative stress, and antioxidant capacity in adults with metabolic syndrome: A randomized crossover clinical trial.
    Hajhashemy Z; Mirenayat FS; Siavash M; Saneei P
    Phytother Res; 2023 Apr; 37(4):1319-1329. PubMed ID: 36428227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.
    Seltzer B
    Clin Interv Aging; 2010 Feb; 5():1-6. PubMed ID: 20169037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.